Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib (JAK1 Inhibitor): Atopic Dermatitis
- Braftovi® (encorafinib) + Erbitux® (cetuximab): 1st line BRAF-mutant Metastatic Colorectal Cancer
- Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab): BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
- COVID-19 Vaccine: COVID-19 Infection (in collaboration with BioNTech)
- Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX): Hemophilia
- Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy): Duchenne Muscular Dystrophy
- Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII): Hemophilia
- Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor): Hemophilia
- Prophylactic Vaccine: Clostridioides difficile infection
- Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal infections (adult, pediatric)
- Prophylactic Vaccine: Meningococcal Infections (adolescent and young adults)
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
- Relugolix combination: Uterine Fibroids, Endometriosis
- Ritlecitinib (JAK3/TEC Inhibitor): Alopecia Areata
- Sasanlimab (PF-06801591) + BCG: Non-Muscle-Invasive Bladder Cancer
- Somatrogon (PF-06836922): Growth Hormone Deficiency (adult, pediatric)
- Talzenna® (talazoparib) + Xtandi® (enzalutamide): 1st Line Metastatic Castration-Resistant Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
- Xtandi® (enzalutamide): Non-metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of May 4, 2021
- Discovery Projects
- 30Phase 1
- 38Phase 2
- 22Phase 3
- 10Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Non-metastatic High-Risk Castration Sensitive Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor and anti PD-1 | BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
Project advanced | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor and anti EGFR | 1st line BRAF-mutant Metastatic Colorectal Cancer | Phase 3 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer | Phase 2 | Product Enhancement | Small Molecule |
Elranatamab Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma (Biologic)
Project advanced | Phase 2 | New Molecular Entity | Biologic |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta® (axicabtagene ciloleucel)forCancer(Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Small Molecule |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
